G.V. Tereshchenko
11 Papers
9 Citations
G.V. Tereshchenko is an academic researcher. The author has contributed to research in topics: Medicine & Hematology. The author has an hindex of 1, co-authored 4 publications.
Chat about Author
Papers
Neurosurgical aspects of the treatment of neuroblastoma patients
S.S. Ozerov,A E Samarin,E.S. Andreev,G.V. Tereshchenko,D.Yu. Kachanov,T.V. Shamanskaya,S.R. Varfolomeeva +6 more
TL;DR: The article discusses the indications and contraindications for neurosurgical interventions in NB patients and addresses the issues of NB metastasis to the brain and cranial bones as well as the opsoclonus-myoclonUS syndrome.
7
The results of therapy in patients with high-risk neuroblastoma: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
T.V. Shamanskaya,S.R. Varfolomeeva,Denis Kachanov,Roman Moiseenko,M.V. Teleshova,D.M. Konovalov,V. Yu. Roshchin,Anna Kazakova,L. Zemtsova,A E Druĭ,M. Ya. Yadgarov,G.V. Tereshchenko,A. P. Shcherbakov,Y. N. Likar,M. N. Sukhov,N. S. Grachev,D. G. Akhaladze,Michael Maschan,A.V. Nechesnyuk,Aleksey V. Pshonkin,Elena Kurnikova,E V Skorobogatova,Lili Khachatryan,Dmitry K. Fomin,Aleksey Maschan,A. G. Rumyantsev,Galina Novichkova +26 more
TL;DR: In this article , the authors retrospectively assessed the effectiveness of therapy in patients with high-risk neuroblastoma (NB) before the introduction of GD2-targeted immunotherapy (IT) into clinical practice.
Effectiveness of cisplatin monotherapy in standard-risk hepatoblastoma
Roman Moiseenko,D. G. Akhaladze,A V Filin,G.S. Rabaev,E. V. Feoktistova,N.N. Merkulov,A. V. Metelin,G.V. Tereshchenko,V.V. Shchukin,T.V. Shamanskaya,S.R. Varfolomeeva,Denis Kachanov +11 more
TL;DR: In this paper , the authors analyzed the effectiveness of cisplatin monotherapy in patients with standard-risk hepatoblastoma (HB) and calculated the overall survival (OS), event-free survival (EFS), where any modification of chemotherapy regimen towards its escalation were considered as an additional event, and progression free survival (PFS).
1